Stock Price Forecast

March 26, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Synaptogenix Inc chart...

About the Company

synaptogenix is a clinical-stage biopharmaceutical company that has historically worked to develop novel therapies for neurodegenerative diseases.

Exchange

NASDAQ

$M

Total Revenue

5

Employees

$3M

Market Capitalization

0.14

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $SNPX News

Synaptogenix, Inc. (SNPX) Stock Historical Prices & Data - Yahoo Finance

7d ago, source: Yahoo Finance

*Close price adjusted for splits.**Adjusted close price adjusted for splits and dividend and/or capital gain distributions. Loading more data ...

Synaptogenix Inc Ordinary Shares

14d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Synaptogenix Inc.

29d ago, source: Wall Street Journal

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Synaptogenix, Inc. Common Stock (SNPX)

3y ago, source: Nasdaq

Nasdaq provides company’s SEC filings, which are financial statements and reports filed electronically with the U.S. Securities and Exchange Commission (SEC) by Quotemedia. The SEC ...

U.S. stocks higher at close of trade; Dow Jones Industrial Average up 1.18%

1mon ago, source: Hosted on MSN

Greenbrook TMS Inc (NASDAQ:GBNH) which lost 46.69% to settle at 0.20 and Synaptogenix Inc (NASDAQ:SNPX) which was down 29.45% to 0.19 at the close. Rising stocks outnumbered declining ones on the ...

Synaptogenix (SNPX) Receives a Buy from Maxim Group

1mon ago, source: ADVFN

In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Synaptogenix (SNPX – Research Report), with a price target of $14.00. The company's shares closed last ...

Sweet Baby Inc. Doesn’t Do What Some Gamers Think It Does

23d ago, source: Kotaku

Sweet Baby Inc. is not the largest narrative design company in the games industry. Nor is it solely responsible for the characters and stories in recent high-profile releases like Alan Wake 2 ...

Synaptogenix, Inc. (SNPX)

1y ago, source: Yahoo Finance

Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders, today announced that its President ...

Synaptogenix, Inc. (SNPX) stock historical prices & data – Yahoo Finance

1y ago, source: Yahoo Finance

*Close price adjusted for splits.**Close price adjusted for splits and dividend and/or capital gain distributions. Loading more data ...

U.S. shares higher at close of trade; Dow Jones Industrial Average up 1.18%

1mon ago, source: Hosted on MSN

Greenbrook TMS Inc (NASDAQ:GBNH) which lost 46.69% to settle at 0.20 and Synaptogenix Inc (NASDAQ:SNPX) which was down 29.45% to 0.19 at the close. Advancing stocks outnumbered falling ones by ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...